The """"""""New Chimeric Antigen Receptors"""""""" project consists of 2 parts. In the first part of this project we are attemping to identify chimeric antigen receptors (CARs) with different antigen specificities than the anti-CD19 chimeric antigen receptors that we have extensive experience with. The first step to finding chimeric antigen receptors with new specificities is to find appropriate targets. We are interested in finding antigenic targets on multiple myeloma or hodgkins lymphoma that could be safely and effectively targeted by CARs. We have spent considerable time and resources in the past year screening normal human tissues for expression of candidate antigens. This is a critical first step in developing new targets because if a target is expressed on normal human tissues, targeting it with chimeric-antigen-receptor-expressing T cells could cause significant toxicity. We have been screening normal tissues by quantitative PCR and by immunohistochemistry. We have identified one antigen with very restricted expression on normal tissues. This antigen is expressed by multiple myeloma cells and some hodgkins lymphoma cells. We have constructed 3 new CAR genes that are designed to target this antigen. We will soon test these new CARs in vitro. The second aspect of the """"""""New Chimeric Antigen Receptor"""""""" project is to explore the use of lentiviral vectors for transducing T cells with CARs. We have a collaboration with Richard Morgan in the Surgery Branch of the NCI and we have obtained a lentiviral vector called pRRLSIN.cPPT.MSCV.coDMF5.oPRE from Dr. Morgan. We have cloned multipe CAR genes into this lentiviral vector after removing the coDMF5 component from the vector. We are testing the new lentiviral CAR vectors in vitro in hopes of developing a new CAR vector for future clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Magalhaes, Isabelle; Kalland, Ingrid; Kochenderfer, James N et al. (2018) CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-? Production Profile. J Immunother 41:73-83
Brudno, Jennifer N; Kochenderfer, James N (2018) Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 15:31-46
Ariza-Heredia, Ella J; Granwehr, Bruno P; Viola, George M et al. (2017) False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. Diagn Microbiol Infect Dis 88:305-307
Kochenderfer, James N; Somerville, Robert P T; Lu, Tangying et al. (2017) Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol 35:1803-1813
Alabanza, Leah; Pegues, Melissa; Geldres, Claudia et al. (2017) Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther 25:2452-2465
Brudno, Jennifer N; Kochenderfer, James N (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321-30
Elumogo, Comfort O; Kochenderfer, James N; Civelek, A Cahid et al. (2016) Pigmented villonodular synovitis mimics metastases on fluorine 18 fluorodeoxyglucose position emission tomography-computed tomography. Quant Imaging Med Surg 6:218-23